Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($1.36), $0.20 worse than the analyst estimate of ($1.16). Revenue for the quarter came in at $14.61 million versus the consensus estimate of $17.99 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.